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Pre-clinical Drug Prioritization












































































The information to deliver
• Network could be drug target
• Jianghui Xiong etc., Pre-clinical drug prioritization via prognosis-guided genetic interaction networks. 
PloS ONE 2010
• “For more than a decade, scientists in systems biology have 
promised that real breakthrough in genetic medicine will 
come when we stop mapping individual genes to 
phenotypes and instead start looking at interacting 
networks. Yet, not much has happened. The field is still 
struggling to define relevant networks and to interpret data 
in terms of those networks.
              The paper by Xiong et al adds considerably to the 





































One of most challenging scientific problems




































The current models used for pre-clinical drug testing Do NOT 
accurately predict how new treatments will act in clinical 
trials
– Heterogeneity in patient populations
– Unpredictable physiology
What’s wrong with our cancer models? NATURE REVIEWS DRUG DISCOVERY,  
2005
What’s wrong with our Disease 
Models





































– Considering gene networks associated with 
cancer outcome in heterogeneous patient 
populations 
– The difficulty of identify effective cancer cures (as 
evidenced by drug resistance) may be a 
consequence of the robustness of this network
– Network (robustness) as drug target
Pre-clinical in silico Cancer Models for Drug action 
study
– Incorporating heterogeneity and in vivo physiology 

































































































Synergistically Infered Nexus ( SIN )
�����1,�2; � � = ���1, �2; � � − ����1; � �+  �(�2; � )� 
























































































Compound in vitro 
screen data














































What is Gene Module? 

































































































Chang H Y et al. PNAS 2005;102:3738-3743
a “wound response” gene 












 -- data associated gene expression with 
patients’ prognosis 




































































































































Inter-Module Cooperation Network  (IMCN) 
for lung cancer suggests that the network robustness highly 















































































































Contribution of various evidence sources 



































Comparing genetic (somatic mutation) and epigenetic (DNA methylation) 





































Compound action on cells




































Use Perturbation Index (PI) to 
quantify Drug action
Hypothesis
– To disrupt/perturb cancer network, the key to success is to simultaneously 








































Benchmarking for pre-clinical drug prioritizing
• Why test?
– Assess the potential application for prioritizing compounds for 
clinical trials, based on the information available in pre-clinical 
stage
• ‘Standard Agent Database’
– Originally created by Boyd [29] and ultimately finalized by the 
NCI
– Compounds which have been submitted to the FDA for review 
as a New Drug Application
– OR compounds that have reached a particular high stage of 
interest at the NCI
• Successful drug list - FDA approved and routinely used drugs 
• Candidate list - the remainder 
• Test what?
– Whether we could statistically discriminate between these two compound 



































Bootstrapping-based assessment of Perturbation Index on 



































Rank of drugs and agents in clinical development for lung cancer 


























































































The Perturbation Index of 
pair-wise combination of lung cancer agents
• Validity of Bortezomib-
Gemcitabine
–  Notable survival benefits in lung 
cancer patients using a Bortezomib + 
gemcitabine/carboplatin  combination 
as first-line treatment (phase II 
clinical trial reported)
• Davies, A.M. et al. J Thorac Oncol 4, 87-92 (2009)
• Validity of Bortezomib-
Paclitaxel
– In an RNA interference (RNAi)-based 
synthetic lethal screen for seeking 
paclitaxel chemosensitizer genes in 
human NSCLC cell line, proteasome is 
the most enriched gene group

















































































As a preclinical in silico modeling tool
– Mirroring drug behavior on natural populations
– Cost-effectiveness




































• Gatekeeper modules as rate-limiting steps in therapeutic treatment
 Drug metabolism and accessibility
 Microenvironment
 immune system modulation 
• Epigenetic plasticity on gatekeeper modules could exploited by 
tumor for attaining resistance to treatment 
– Drug accessibility        <- Multi Drug Resistance 
– Microenvironment      <- Inflammatory
– Immune modulation   <- Complement activation 
• Battle against cancer
• know the history of tumorigenesis <etiology>
• know future survival strategy of tumor under therapeutic 
interventions





































A new perspective to understand principle of drug 
combination in
Traditional Chinese Medicine ?
• 君 - King
• 君 - Minister
• 君 - Assistant
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